Thank you, Madam Chair. Thank you to all the witnesses for appearing before committee.
As you know, Mr. Casey, since our early days of COVID-19, the government was focused on a three-pronged approach. First was to try to secure leading international vaccines. Second was to invest in the most promising Canadian manufacturers of therapeutics and vaccines. Third was to develop biomanufacturing capacity. Central to that strategy was the establishment of a vaccine task force.
Could you share with us your opinion of the vaccine task force? After all, leading scientists and industry experts sit on that committee. They've been doing their due diligence. Could you tell us whether that was an effective approach or not?